Erratum to the association between the ERCC1/2 polymorphisms and radiotherapy efficacy in 87 patients with non-small cell lung cancer
Erratum to: J Thorac Dis 2021;13:3126-36
In the article (1) titled “the association between the ERCC1/2 polymorphisms and radiotherapy efficacy in 87 patients with non-small cell lung cancer” published in Journal of Thoracic Disease (J Thorac Dis 2021;13:3126-36. doi: 10.21037/jtd-21-755), there were some errors in the Results section.
(I) There is a typo in a confidence interval (CI) value.
Original sentence: The median PFS of patients with the G allele was 18.9 months (95% CI: 13.960–24.780), which was significantly higher than that of patients with the A allele (11.3 months, 95% CI: 8.655–14.005); the difference between the two groups was statistically significant (P=0.040).
Corrected sentence: The median PFS of patients with the G allele was 18.9 months (95% CI: 13.960–23.780), which was significantly higher than that of patients with the A allele (11.3 months, 95% CI: 8.655–14.005); the difference between the two groups was statistically significant (P=0.040).
(II) There were errors in Table 3. The corrected version of Table 3 is included below.
Table 3
| Gene | MST (months) | 95% CI | P | Median PFS (months) | 95% CI | P |
|---|---|---|---|---|---|---|
| rs11615 | ||||||
| AA | 6.77 | 0–14.05 | 0.000 | 5.13 | 0–15.13 | 0.019 |
| AG | 19.77 | 11.14–28.40 | 11.33 | 5.76–16.91 | ||
| GG | 30.90 | 12.83–48.97 | 18.87 | 13.96–23.78 | ||
| A allele | 16.17 | 9.10–23.24 | 0.003 | 11.33 | 8.66–14.01 | 0.040 |
| G allele | 30.90 | 12.83–48.97 | 18.87 | 13.96–23.78 | ||
| rs3212961 | ||||||
| GG | 24.77 | 4.75–44.79 | 0.735 | 11.53 | 6.41–16.66 | 0.910 |
| GT | 23.97 | 15.75–32.19 | 18.07 | 12.67–23.47 | ||
| TT | 24.93 | 9.37–40.49 | 11.60 | 5.28–17.92 | ||
| G allele | 24.93 | 18.95–30.91 | 0.441 | 16.17 | 11.84–20.50 | 0.897 |
| T allele | 24.77 | 4.75–44.79 | 11.53 | 6.41–16.66 | ||
| rs3212986 | ||||||
| AA | 71.13 | 0–160.416 | 0.092 | 15.53 | 0–38.01 | 0.718 |
| AC | 29.10 | 18.92–39.28 | 18.70 | 11.91–25.49 | ||
| CC | 21.53 | 12.97–30.09 | 14.67 | 8.85–20.49 | ||
| A allele | 30.90 | 15.68–46.12 | 0.086 | 18.07 | 8.85–20.49 | 0.423 |
| C allele | 21.53 | 12.97–30.09 | 14.67 | 11.89–24.25 | ||
| rs13181 | ||||||
| TT | 24.93 | 16.19–33.67 | 0.692 | 14.67 | 10.17–19.17 | 0.921 |
| TG | 24.77 | 12.67–36.87 | 19.07 | 9.96–28.19 | ||
| rs238406 | ||||||
| TT | 16.17 | 0–36.26 | 0.686 | 11.33 | 8.92–13.74 | 0.143 |
| TG | 28.67 | 22.72–34.62 | 21.50 | 16.86–26.14 | ||
| GG | 19.80 | 13.76–25.84 | 11.30 | 6.67–15.93 | ||
| T allele | 26.83 | 21.44–32.22 | 0.562 | 16.83 | 12.16–21.50 | 0.097 |
| G allele | 19.80 | 13.76–25.84 | 11.30 | 6.67–15.93 | ||
| rs1799793 | ||||||
| CC | 25.40 | 18.74–32.05 | 0.222 | 15.53 | 11.79–19.27 | 0.411 |
| CT | 19.07 | 10.48–27.66 | 16.13 | 2.89–29.37 |
NSCLC, non-small cell lung cancer; CI, confidence interval; MST, median overall survival time; PFS, progression-free survival.
Click here to view the updated version of the article.
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
References
- Jiang C, Guo Y, Li Y, et al. The association between the ERCC1/2 polymorphisms and radiotherapy efficacy in 87 patients with non-small cell lung cancer. J Thorac Dis 2021;13:3126-36. [Crossref] [PubMed]
